Fluoroquinolones Need REMS With Communication Plan, US FDA Panel Says
This article was originally published in SRA
Executive Summary
A joint panel of the US Food and Drug Administration says that fluoroquinolones once again need a risk evaluation and mitigation strategy (REMS) to ensure providers and patients understand the risks of the medication1.